Skip to main content
TipRanks
Go Ultimate75% OFF

Hikma Pharmaceuticals (H5P) Stock Forecast & Price Target

4 Followers
See the Price Targets and Ratings of:

H5P Analyst Ratings

Strong Buy
5Ratings
4Buy1Hold0Sell
Based on 5 analysts giving stock ratings to Hikma Pharmaceuticals in the past 3 months

H5P Stock 12 Month Forecast

€23.15▲(14.93% Upside)
Based on 5 Wall Street analysts offering 12 month price targets for Hikma Pharmaceuticals in the last 3 months. The average price target is EUR 23.15 with a high forecast of EUR 24.62 and a low forecast of EUR 20.42. The average price target represents a 14.93% change from the last price of EUR 20.14.
Highest Price Target€24.62Average Price Target€23.15Lowest Price Target€20.42

Detailed List of Analyst Forecasts​

Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
Analyst forecasts for DE:H5P
Price TargetArticle
Berenberg Bank€25.22→€24.62buy22.27%UpsideReiterated11/09/26
Barclays€20.42hold1.39%UpsideReiterated11/06/26
Jefferies€24.32buy20.77%UpsideReiterated11/05/26
Deutsche Bank €24.62buy22.27%UpsideReiterated11/03/26
Citi€22.46→€21.74buy7.95%UpsideReiterated10/13/26
J.P. Morgan€24.02buy19.28%UpsideReiterated03/03/26
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
PVLAPalvella Therapeutics
IRLAIRulya Therapeutics
RZLTRezolute
PTGXProtagonist Therapeutics
CTMXCytomX Therapeutics

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Hikma Pharmaceuticals

3 Months
Beatrice Fairbairn
Beatrice FairbairnBerenberg Bank
Success Rate6/6 ratings generated profit
100%
Average Return
+8.98%

Copying Beatrice Fairbairn's trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +8.98% per trade.

1 Year
Beatrice Fairbairn
Beatrice FairbairnBerenberg Bank
Success Rate6/6 ratings generated profit
100%
Average Return
+15.87%

Copying Beatrice Fairbairn's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +15.87% per trade.

2 Years
Beatrice Fairbairn
Beatrice FairbairnBerenberg Bank
Success Rate6/6 ratings generated profit
100%
Average Return
+16.18%

Copying Beatrice Fairbairn's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +16.18% per trade.

H5P Analyst Recommendation Trends

02468Dec 25Jan 26Feb 26Mar 26Apr 26May 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26
Monthly rating counts for H5P
RatingJul 26Aug 26Sep 26Oct 26Nov 26
Strong Buy00000
Buy36776
Hold00112
Sell11000
Strong Sell00000
total47888

In the current month, H5P has received 6 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. H5P average Analyst price target in the past 3 months is 23.15.

H5P Financial Forecast

€-1€-0.25€0.5€1.25€2Q2 2025Q2 2026Q4 2026
High€1.00
Consensus€1.00
Low€1.00

H5P Earnings Forecast

Next quarter’s earnings estimate for H5P is EUR 1.00 with a range of EUR 1.00 to EUR 1.00. The previous quarter’s EPS was EUR 1.12. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.

€1.4B€1.5B€1.5B€1.5B€1.5BQ2 2025Q2 2026Q4 2026
High€1.53B
Consensus€1.53B
Low€1.53B

H5P Sales Forecast

Next quarter’s sales forecast for H5P is EUR 1.53B with a range of EUR 1.53B to EUR 1.53B. The previous quarter’s sales results were EUR 1.54B. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.

H5P Stock Forecast FAQ

What is DE:H5P’s average 12-month price target, according to analysts?
Based on analyst ratings, Hikma Pharmaceuticals’s 12-month average price target is €23.15.
What is DE:H5P’s upside potential, based on the analysts’ average price target?
Hikma Pharmaceuticals has 14.93% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Hikma Pharmaceuticals a Buy, Sell or Hold?
Hikma Pharmaceuticals has a consensus rating of Strong Buy, which is based on 4 buy ratings, 1 hold ratings and 0 sell ratings.
What is Hikma Pharmaceuticals’s share price target?
The average share price target for Hikma Pharmaceuticals is €23.15. This is based on 5 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is €24.62, and the lowest forecast is €20.42. The average share price target represents a 14.93% increase from the current price of €20.14.
What do analysts say about Hikma Pharmaceuticals?
Hikma Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Street analysts.
How can I buy shares of Hikma Pharmaceuticals?
To buy shares of DE:H5P, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.